Covance ($CVD) is joining forces with GNS Healthcare to use the company's big data know-how to create models for drug-development success.
GNS touts its supercomputer-powered Reverse Engineering and Forward Simulation analytics, and the company will put its expertise toward determining whether patients in clinical trials are likely to benefit from experimental drugs.
GNS CEO Colin Hill told FierceBiotech IT that the partnership with Covance is GNS' first work with a CRO, and the duo is first targeting Type II diabetes drugs, a bustling wing of pharmaceutical development.
As CROs scramble to nail down contracts with pharmas developing diabetes treatments, having access to GNS' models will help Covance get a leg up, Hill said.
"If you're in Big Pharma and you're trying to develop a drug for Type II diabetes, the fact that the CRO that is going to run the trial for you has a predictive model of showing insights of what parameters are likely to lead to greater success, that's game-changing," he told FierceBiotech IT.
Neither company disclosed the terms of the deal, but GNS plans to have its models ready for Covance by next year.
- here's the release
- read more in FierceBiotech IT